TABLE 1.
Clinical characteristics of the iMCD cohorts
| iMCD‐TAFRO (N = 6) | iMCD‐NOS (N = 8) | |
|---|---|---|
| Age, y; mean (range) | 27 (1‐61) | 38 (14‐58) |
| Sex, female:male | 1:5 | 4:4 |
| TAFRO criteria, present/assessed (%) | ||
| Thrombocytopenia | 6/6 (100) | 2/4 (50) |
| Anasarca or oedema | 6/6 (100) | 1/7 (14) |
| Constitutional symptoms | 6/6 (100) | 6/8 (75) |
| Reticulin myelofibrosis | 3/4 (75) | 1/1 (100) |
| Renal dysfunction | 4/6 (67) | 0/5 (0) |
| Hepatomegaly and/or splenomegaly | 4/6 (67) | 3/7 (43) |
| Inflammation and organ dysfunction | ||
| CRP, mg/dL | n = 5 | n = 3 |
| Mean (SD) | 15.9 (9.9) | 5.8 (7.6) |
| IL‐6, pg/mL | n = 5 | No data |
| Mean (SD) | 307.7 (92.3) | |
| VEGF, pg/mL | n = 3 | No data |
| Mean (SD) | 380.7 (107.0) | |
| IgG, mg/dL | n = 5 | n = 2 |
| Mean (SD) | 1518 (951) | 1525 (218) |
| Albumin, g/dL | n = 5 | n = 4 |
| Mean (SD) | 2.5 (0.54) | 3.6 (0.73) |
| Creatinine, mg/dL | n = 6 | n = 4 |
| Mean (SD) | 1.2 (0.94) | 1.0 (0.27) |
| Treatment prior to lymph node biopsy | ||
| Intravenous immunoglobulin | 2/6 (33) | 0/8 (0) |
| Corticosteroids | 1/6 (17) | 1/8 (13) |
| Other treatments | 0/6 (0) | 0/8 (0) |
Each laboratory value represents the closest laboratory value to the date of diagnosis within 30 days prior to or following biopsy.
Abbreviations: CRP, C‐reactive protein; IgG, immunoglobulin G.; IL‐6, interleukin‐6; iMCD‐NOS, iMCD‐not‐otherwise‐specified; iMCD‐TAFRO, iMCD‐thrombocytopenia‐anasarca‐fever‐renal dysfunction‐organomegaly; SD, standard deviation; VEGF, vascular endothelial growth factor.